Cabozantinib superior to sunitinib as a first-line therapy for advanced kidney cancer

Results from the phase II CABOSUN clinical trial, showing cabozantinib to be superior to sunitinib as first-line treatment for advanced kidney cancer, were presented at the European Society for Medical Oncology (ESMO) congress in Copenhagen this week. CABOSUN is a phase II randomised controlled clinical trial comparing cabozantinib and sunitinib in previously untreated patients with intermediate- […]

read more

Sutent shown to improve disease-free survival in people with kidney cancer

Results from the S-TRAC study were presented at the European Society of Medical Oncology (ESMO) congress in Copenhagen this week. The results show that Sutent (sunitinib) improved disease-free survival in patients with localised kidney cancer that had been surgically removed; a group considered high-risk for relapse. In the phase III S-TRAC trial, patients were followed for 5 years […]

read more

Sutent (sunitinib) improves disease-free survival in kidney cancer patients at high risk of recurrence following surgery

Pfizer announced this week that the phase III S-TRAC clinical trial of sunitinib versus placebo in patients with renal cell carcinoma (RCC) who are at hight risk of recurrence after surgery has met its primary endpoint of improving disease-free survival (DFS). The S-TRAC trial is the first RCC trial of a tyrosine kinase inhibitor (TKI) to […]

read more

Adjuvant sunitinib or sorafenib don’t prevent recurrence of kidney cancer

Results from the ASSURE clinical trial have recently been published in the Lancet. ASSURE compared the effect of adjuvant sorafenib or sunitinib with placebo in renal cell carcinoma (RCC) patients who had had their tumours surgically removed, and who had a high risk for recurrence. The trial was conducted in the US and Canada, and initial […]

read more

Sunitinib vs everolimus for advanced non-clear cell kidney cancer

In a recent study published in the journal Lancet Oncology, researchers compared everolimus versus sunitinib in 108 patients with metastatic papillary, chromophobe, or unclassified non–clear-cell renal cell carcinoma (RCC) in a phase 2 randomised, industry-sponsored clinical trial. Nearly two thirds of the patients had papillary histology. Progression-free survival was longer with sunitinib in patients with […]

read more

Adjuvant sunitinib or sorafenib for high risk kidney cancer

A study published in The Lancet last week reported that adjuvant treatment (treatment following surgery) with the VEGF receptor tyrosine kinase inhibitors sorafenib or sunitinib showed no survival benefit relative to placebo in a definitive phase 3 study. Furthermore, substantial treatment discontinuation occurred because of excessive toxicity, despite dose reductions. These results provide a strong […]

read more
Showing 111 to 116 of 116 results
  TOP